Journal of Clinical Oncology
Articles in this Issue
Acceptability of a narrative video intervention to promote clinical trial decision-making among Black women with breast cancer.
e23192 Background: Black women are more likely to present with advanced stage disease and to die following a breast cancer...
Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases.
2597 Background: RPx is an investigational HSV-1-based oncolytic immunotherapy platform including RP1 (vusolimogene oderpa...
Preliminary phase 1 results of a MICA/B-targeted CAR T cell designed to overcome solid tumor escape mechanisms and avoid the requirement for conditioning chemotherapy.
2560 Background: FT836 is a multi-engineered CAR T cell targeting the conserved α3 domain of MICA/B stress ligands, enabli...
Machine learning to identify biomarkers of response to immunotherapy in <i>KRAS</i> wildtype ( <i>KRASwt)</i> non-small cell lung cancer (NSCLC).
e20609 Background: KEAP1 and STK11 are associated with resista...
FUEL-IT Lung: Fasting to unleash and enhance lung cancer immunotherapy—A VA Lung Precision Oncology Program trial.
TPS8666 Background: Single-agent PD-(L)1 inhibitors are standard first-line therapy for advanced non-small cell lung cance...
Optimizing post-prostatectomy management: A machine learning tool to identify low-risk patients and minimize unnecessary burden in localized prostate cancer.
e17121 Background: Biochemical recurrence (BCR) is a key early indicator of disease progression in localized prostate canc...
Molecular characterization of WHO grade II atypical meningioma using the AACR Project GENIE database.
2088 Background: Atypical meningioma (AM) is a WHO grade II neoplasm arising from meningeal arachnoid cap cells and is dis...
Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.
3110 Background: In 2025 the EMA and FDA expanded the approval of selumetinib (SELU; ARRY-142886, AZD6244) to adults with...
Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without <i>FLT3</i> mutation.
6538 Background: The FLT3 gene plays a major role in acute myeloid leukemia and frequently overexpressed irrespective of i...
Correlative analysis of phase II trial of olaparib and durvalumab in patients with <i>IDH</i> -mutated cholangiocarcinoma.
4157 Background: IDH1/2 mutations occur in ~25% of cholangiocarcinomas (CCAs). Preclinical studies sug...
Comparative outcomes of prophylactic cranial irradiation and brain surveillance in limited-stage small cell lung cancer: A systematic review and meta-analysis.
e20142 Background: Prophylactic cranial irradiation (PCI) improves survival outcomes versus no PCI in limited-stage small-...
Timing of adjuvant nivolumab and survival outcomes in bladder cancer: A real-world analysis.
e16562 Background: Adjuvant nivolumab improves outcomes in high-risk muscle-invasive bladder cancer (MIBC) when initiated...
Bridging the gap in endometrial cancer: A multi-center initiative to standardize biomarker testing and community team-based care.
e23321 Background: The incidence of endometrial cancer (EC) has increased in the past decade. Integration of biomarker (BM...
Machine learning–integrated routine biomarkers for breast cancer risk stratification: A scalable strategy for resource-limited settings.
e12557 Background: Early breast cancer diagnosis is essential for improving survival outcomes and optimizing healthcare re...
Diagnostic performance of methylene blue vital staining for early detection of oral epithelial dysplasia and carcinoma in high-risk populations: A meta-analysis.
e18008 Background: Early detection of oral precancer and cancer significantly improves prognosis, yet reliable and afforda...
Dentist-led systematic oral education programs in the prevention of radiation-induced oral toxicities in patients with head and neck cancer (BRIGHT): A randomized clinical trial.
12144 Background: Radiotherapy-induced oral toxicity (RIOT) is a common complication in patients with head and neck cancer...
Survival outcome of sandwich therapy with induction chemoimmunotherapy followed by concurrent chemoradiotherapy and sequential immune maintenance therapy in locally advanced unresectable esophageal squamous cell carcinoma (ESCC) patients: A multi-center prospective study.
4068 Background: PD-1 inhibitor, combined with chemotherapy, is recommended in first-line treatment for metastatic ESCC, b...
waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).
TPS7104 Background: DLBCL is a heterogeneous malignancy broadly categorized into 3 subtypes: activated B-cell–like (ABC) D...
Effect of dental prophylaxis on long-term systemic risks in therapy-induced oral mucositis: A real-world cohort analysis.
e24195 Background: Oral ulcerating mucositis (OUM) is a common complication of radiation and antineoplastic therapy, often...
Midday immune checkpoint inhibitor (ICI) infusion influence on survival in patients with metastatic cancer: A real-world chrono-immunotherapy study.
11162 Background: Circadian rhythms regulate immune activity, and earlier ICI dosing has been linked to better survival. H...
Laparoscopic versus open distal gastrectomy for clinical T4a gastric cancer: Short-term outcomes and interim survival analysis of the UMC-UPPERGI-01 randomized clinical trial.
e16142 Background: Laparoscopic distal gastrectomy (LDG) is widely accepted for early and advanced stages gastric cancer (...
Oncologists’ knowledge, clinical practices, barriers and facilitators of cardio-oncology guideline-concordant care.
e24011 Background: Cancer and cardiovascular (CV) disease are leading global causes of morbidity and mortality, with risin...
Association of inpatient outcomes with carcinoid syndrome among malignant neuroendocrine tumor hospitalizations in the United States: NIS 2016–2022.
e16320 Background: Carcinoid syndrome (CS) may contribute to inpatient morbidity and resource utilization among patients w...
Real-world evidence of immunotherapy-associated outcomes in patients with hepatocellular carcinoma: Insights from TriNetX database.
e16193 Background: Immunotherapy has become a cornerstone in the management of hepatocellular carcinoma (HCC), with immune...
An early on-treatment "coordinated inflammatory niche" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).
3600 Background: The SYLT026 trial is a phase II study investigating the efficacy and safety of cadonilimab (an anti-CTLA-...